Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CGEN

Compugen Ltd

Apr 27 • 04:00PM ET

2.92

-0.18 -5.81 %

Healthcare • Biotechnology • Israel • Micro • NASD

Peers: MRNA VRTX ALLO CRSP FATE NTLA EDIT SGMO BLUE CLLS

| Held by: SPDW GWX

Scroll to Statements

Index	-	P/E	7.91	EPS (ttm)	0.37	Insider Own	2.19%	Shs Outstand	94.55M	Perf Week	1.39%
Market Cap	276.10M	Forward P/E	-	EPS next Y	-0.18	Insider Trans	-2.17%	Shs Float	92.49M	Perf Month	41.75%
Enterprise Value	133.42M	PEG	-	EPS next Q	-0.07	Inst Own	13.63%	Short Float	1.21%	Perf Quarter	43.84%
Income	35.34M	P/S	3.79	EPS this Y	-156.84%	Inst Trans	0.13%	Short Ratio	3.33	Perf Half Y	74.85%
Sales	72.76M	P/B	2.69	EPS next Y	18.52%	ROA	26.00%	Short Interest	1.12M	Perf YTD	90.85%
Book/sh	1.09	P/C	1.90	EPS next 5Y	-	ROE	44.84%	52W High	3.23 -9.74%	Perf Year	97.30%
Cash/sh	1.54	P/FCF	-	EPS past 3/5Y	- -	ROIC	33.61%	52W Low	1.23 137.40%	Perf 3Y	397.02%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	113.28% 105.20%	Gross Margin	87.29%	Volatility	6.89% 6.62%	Perf 5Y	-67.15%
Dividend TTM	-	EV/Sales	1.83	EPS Y/Y TTM	333.90%	Oper. Margin	43.05%	ATR (14)	0.17	Perf 10Y	-57.62%
Dividend Ex-Date	-	Quick Ratio	6.56	Sales Y/Y TTM	161.14%	Profit Margin	48.57%	RSI (14)	66.05	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.56	EPS Q/Q	978.77%	SMA20	11.96%	Beta	2.96	Target Price	4.40
Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	4477.29%	SMA50	29.86%	Rel Volume	2.81	Prev Close	3.10
Employees	75	LT Debt/Eq	0.02	Earnings	Mar 02 BMO	SMA200	64.13%	Avg Volume	337.19K	Price	2.92
IPO	Aug 11, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	900.00% 3018.23%	Trades		Volume	946,024	Change	-5.81%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-07-26	Initiated	Lake Street	Buy	$6
Jan-07-26	Initiated	H.C. Wainwright	Buy	$4
Jan-13-25	Initiated	Oppenheimer	Outperform	$4
Aug-05-22	Downgrade	Jefferies	Buy → Hold	$2
May-26-20	Resumed	JMP Securities	Mkt Outperform	$18
May-13-20	Initiated	Stifel	Buy	$19
May-07-20	Initiated	SVB Leerink	Outperform
Apr-22-20	Initiated	ROTH Capital	Buy	$28
Mar-24-20	Initiated	SunTrust	Buy	$16
Jan-16-20	Initiated	Cantor Fitzgerald	Overweight	$10
Mar-29-18	Initiated	Oppenheimer	Outperform
Feb-01-16	Resumed	Oppenheimer	Outperform
Oct-15-15	Initiated	FBR Capital	Outperform	$14
Apr-23-15	Resumed	Jefferies	Buy	$11
Apr-21-15	Initiated	Oppenheimer	Outperform	$11
Feb-07-14	Initiated	MLV & Co	Buy	$14
Dec-28-09	Reiterated	Cantor Fitzgerald	Buy	$5 → $12
Jul-29-09	Initiated	Cantor Fitzgerald	Buy	$6.50

Show Previous Ratings

Apr-09-26 07:00AM	Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference (PR Newswire) +8.30%
Mar-03-26 08:03PM	Compugen Ltd (CGEN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -11.11% +7.00%
Mar-02-26 12:31PM	Compugen Ltd. Q4 2025 Earnings Call Summary (Moby) +24.31%
08:15AM	Compugen (CGEN) Beats Q4 Earnings and Revenue Estimates (Zacks)
07:17AM	Compugen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Compugen Reports Fourth Quarter and Full Year 2025 Results (PR Newswire)
Feb-27-26 07:22AM	Compugen Ltd (CGEN) Q4 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-26-26 09:55AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-25-26 07:25PM	Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates (Zacks)
Feb-19-26 05:35PM	Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.29%
07:00AM	Compugen to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-17-26 07:00AM	Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026 (PR Newswire)
Feb-12-26 07:00AM	Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors (PR Newswire)
Dec-17-25 07:00AM	Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million (PR Newswire)
Nov-12-25 10:01AM	Compugen Ltd (CGEN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
08:15AM	Loading…
Nov-10-25 08:15AM	Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:16AM	Compugen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Third Quarter 2025 Results (PR Newswire)
Nov-07-25 07:24AM	Compugen Ltd (CGEN) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-06-25 06:55PM	Certara, Inc. (CERT) Q3 Earnings Surpass Estimates (Zacks)
Nov-04-25 07:00AM	Compugen to Participate in Stifel 2025 Healthcare Conference (PR Newswire) -6.94%
Nov-03-25 05:15PM	Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-27-25 07:00AM	Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 (PR Newswire)
Oct-13-25 07:00AM	Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 (PR Newswire) +21.08%
Oct-06-25 07:00AM	Compugen to Present at SITC 2025 (PR Newswire) +9.82%
Sep-08-25 07:00AM	Compugen to Present Research at the Single Cell Genomics 2025 Conference (PR Newswire)
Aug-28-25 07:00AM	Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-06-25 08:20AM	Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:19AM	Compugen: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Second Quarter 2025 Results (PR Newswire)
07:00AM	Loading…
Jul-28-25 07:00AM	Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025 (PR Newswire)
Jul-23-25 07:00AM	Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025 (PR Newswire)
Jul-21-25 07:00AM	Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer (PR Newswire)
Jun-24-25 02:07PM	Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last? (Zacks)
10:42AM	Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
10:38AM	XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? (Zacks)
08:54AM	Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength? (Zacks)
07:56AM	RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
07:50AM	Graham (GHM) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
07:31AM	GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last? (Zacks)
04:41AM	Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength? (Zacks)
Jun-17-25 11:10AM	Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? (Zacks)
07:38AM	EchoStar (SATS) Moves 49.1% Higher: Will This Strength Last? (Zacks)
Jun-12-25 07:00AM	Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences (PR Newswire)
May-20-25 03:03AM	Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline (GuruFocus.com)
May-19-25 11:55AM	Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
10:53AM	Compugen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports First Quarter 2025 Results (PR Newswire)
May-15-25 05:30PM	Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-14-25 06:35PM	Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-13-25 07:00AM	Compugen Announces Leadership Transitions Effective September 2025 (PR Newswire)
May-12-25 05:25PM	Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates (Zacks)
May-08-25 05:35PM	McKesson (MCK) Tops Q4 Earnings Estimates (Zacks)
May-05-25 07:00AM	Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025 (PR Newswire) -7.43%
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-26-25 07:00AM	Compugen to Participate in Multiple Virtual Investor Conferences in April 2025 (PR Newswire)
Mar-23-25 08:29AM	Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-05-25 02:04AM	Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) +7.74%
Mar-04-25 08:15AM	Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.18%
08:15AM	Compugen Reports Fourth Quarter and Full Year 2024 Results (PR Newswire)
07:22AM	Compugen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	/C O R R E C T I O N -- Compugen Ltd./ (PR Newswire)
Mar-03-25 07:00AM	Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference (PR Newswire) -5.73%
Feb-26-25 07:00AM	Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen with Ultima Genomics' Single Cell Genomics Sequencing Technology (PR Newswire)
Feb-18-25 07:00AM	Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025 (PR Newswire)
Feb-04-25 07:00AM	Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-08-25 07:00AM	Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors (PR Newswire)
Nov-27-24 07:00AM	Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies (PR Newswire) +5.92%
Nov-13-24 02:08AM	Compugen Ltd (CGEN) Q3 2024 Earnings Call Highlights: Promising Developments and Strategic ... (GuruFocus.com)
Nov-12-24 11:05AM	Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates (Zacks) -8.05%
09:56AM	Compugen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Third Quarter 2024 Results (PR Newswire)
Nov-11-24 07:00AM	Compugen to Participate in Stifel 2024 Healthcare Conference (PR Newswire)
Nov-05-24 09:00AM	Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024 (PR Newswire)
Oct-29-24 07:00AM	Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (PR Newswire)
Oct-07-24 07:00AM	Compugen to Present New Clinical Data at SITC 2024 (PR Newswire)
Sep-11-24 12:00PM	Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Sep-09-24 07:00AM	Compugen to Present at Single Cell Genomics 2024 Conference (PR Newswire) +8.20%
Aug-29-24 07:00AM	Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +6.84%
Aug-26-24 12:20PM	Can Compugen (CGEN) Run Higher on Rising Earnings Estimates? (Zacks)
Aug-06-24 08:25AM	Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:22AM	Compugen: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports Second Quarter 2024 Results (PR Newswire)
Jul-30-24 06:52AM	Compugen receives FDA approval for Phase I trial of solid tumour treatment (Clinical Trials Arena)
Jul-29-24 07:00AM	Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors (PR Newswire)
Jul-23-24 07:00AM	Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 (PR Newswire)
Jun-17-24 07:00AM	Compugen to Present at Upcoming Antibody Industrial Symposium (PR Newswire) -5.31%
Jun-04-24 09:55AM	Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
May-30-24 07:00AM	Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig (PR Newswire) -7.98%
May-21-24 08:08AM	Compugen Ltd. (NASDAQ:CGEN) Q1 2024 Earnings Call Transcript (Insider Monkey) +6.90%
May-20-24 11:52AM	CGEN Stock Earnings: Compugen Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -17.54%
08:10AM	Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:07AM	Compugen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Compugen Reports First Quarter 2024 Results (PR Newswire)
May-16-24 07:00AM	Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential (PR Newswire)
May-15-24 09:57AM	Compugen Names David Silberman CFO (MT Newswires) +5.74%
07:00AM	Compugen Appoints David Silberman as Chief Financial Officer (PR Newswire)
May-06-24 07:00AM	Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 (PR Newswire)
Apr-25-24 07:00AM	Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 (PR Newswire)

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Levine Zurit	SVP, Business Development	Apr 24 '26	Option Exercise	1.15	2,000	2,300	31,375	Apr 27 04:03 PM
Levine Zurit	SVP, Business Development	Apr 24 '26	Sale	3.20	2,000	6,400	29,375	Apr 27 04:03 PM
Ophir Eran	President and CEO	Apr 24 '26	Option Exercise	0.83	5,000	4,146	16,375	Apr 27 04:02 PM
Ophir Eran	President and CEO	Apr 24 '26	Sale	3.20	5,000	16,000	11,375	Apr 27 04:02 PM
Ophir Eran	Officer	Apr 24 '26	Proposed Sale	2.92	5,000	14,600		Apr 27 06:52 AM
Levine Zurit	Officer	Apr 24 '26	Proposed Sale	2.92	4,000	11,680		Apr 27 06:40 AM
Ophir Eran	President and CEO	Apr 14 '26	Option Exercise	0.83	5,000	4,146	16,375	Apr 15 04:10 PM
Ophir Eran	President and CEO	Apr 14 '26	Sale	2.90	5,000	14,521	11,375	Apr 15 04:10 PM
Levine Zurit	SVP, Business Development	Apr 14 '26	Option Exercise	1.15	2,000	2,300	31,375	Apr 15 04:07 PM
Levine Zurit	SVP, Business Development	Apr 14 '26	Sale	2.80	2,000	5,600	29,375	Apr 15 04:07 PM
Ophir Eran	Officer	Apr 14 '26	Proposed Sale	2.76	5,000	13,800		Apr 15 06:38 AM
Levine Zurit	Officer	Apr 14 '26	Proposed Sale	2.76	2,000	5,520		Apr 15 06:16 AM
Levine Zurit	SVP, Business Development	Apr 10 '26	Option Exercise	1.03	3,125	3,233	32,500	Apr 13 04:04 PM
Levine Zurit	SVP, Business Development	Apr 10 '26	Sale	2.56	3,125	8,012	29,375	Apr 13 04:04 PM
Levine Zurit	Officer	Apr 10 '26	Proposed Sale	2.48	2,000	4,960		Apr 13 07:28 AM
Levine Zurit	SVP, Business Development	Apr 08 '26	Option Exercise	0.89	5,375	4,778	34,750	Apr 09 04:05 PM
Levine Zurit	SVP, Business Development	Apr 07 '26	Option Exercise	0.83	2,500	2,073	31,875	Apr 09 04:05 PM
Levine Zurit	SVP, Business Development	Apr 08 '26	Sale	2.42	5,375	13,008	29,375	Apr 09 04:05 PM
Levine Zurit	SVP, Business Development	Apr 07 '26	Sale	2.30	2,500	5,750	29,375	Apr 09 04:05 PM
Levine Zurit	SVP, Business Development	Apr 01 '26	Option Exercise	0.92	3,500	3,223	32,875	Apr 03 07:31 AM
Levine Zurit	SVP, Business Development	Apr 01 '26	Sale	2.20	3,500	7,700	29,375	Apr 03 07:31 AM
Ophir Eran	President and CEO	Apr 01 '26	Option Exercise	0.83	5,625	4,664	17,000	Apr 03 07:29 AM
Ophir Eran	President and CEO	Apr 01 '26	Sale	2.21	5,625	12,413	11,375	Apr 03 07:29 AM
Ophir Eran	Officer	Apr 01 '26	Proposed Sale	2.13	5,625	11,981		Apr 02 10:06 AM
Levine Zurit	SVP, Business Development	Mar 26 '26	Option Exercise	0.83	11,875	9,847	41,250	Mar 30 06:04 PM
Levine Zurit	SVP, Business Development	Mar 26 '26	Sale	2.04	11,875	24,187	29,375	Mar 30 06:04 PM
Levine Zurit	Officer	Mar 26 '26	Proposed Sale	2.06	24,375	50,212		Mar 26 10:42 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGEN

Compugen Ltd

Upgrade your Finviz experience